Literature DB >> 24094837

Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand.

Ratha-Korn Vilaichone1, Pornpen Gumnarai, Thawee Ratanachu-Ek, Varocha Mahachai.   

Abstract

The objectives of this study are to survey the antibiotic-resistant pattern of Helicobacter pylori infection in different geographical locations in Thailand and to determine factors associated with antibiotic resistance. Dyspeptic patients undergoing upper gastrointestinal endoscopy from the Northern, Northeastern, Central, and Southern regions of Thailand between January 2004 and December 2012 were enrolled in this study. Two antral gastric biopsies were obtained for culture; susceptibility tests were performed using E-test. A total of 3964 were enrolled, and 1350 patients (34.1%) were infected with H. pylori as identified by rapid urease test. Cultures were positive in 619 isolates. E-test for amoxicillin, clarithromycin, metronidazole, and tetracycline were successful in 400 isolates and for levofloxacin and ciprofloxacin in 208 isolates. Antibiotic resistance was present in 50.3% including amoxicillin 5.2%, tetracycline 1.7%, clarithromycin 3.7%, metronidazole 36%, ciprofloxacin 7.7%, levofloxacin 7.2%, and multi-drugs in 4.2%. Clarithromycin resistance was significantly more common in those older than 40 years (i.e., 100% versus 0%; P = 0.04). The prevalence of metronidazole resistant in Southern Thailand was significantly higher than in the Northeastern region (66.7% versus 33.3% P = 0.04). Metronidazole resistance remains the most common antibiotic resistant type of H. pylori in Thailand. The pattern of H. pylori antibiotic resistance over 9 years demonstrated a fall in clarithromycin resistance such that currently age >40 years is a predictor for clarithromycin resistance in Thailand. Quinolone resistance is a growing problem.
© 2013.

Entities:  

Keywords:  Drug resistance; Helicobacter pylori; Thailand

Mesh:

Substances:

Year:  2013        PMID: 24094837     DOI: 10.1016/j.diagmicrobio.2013.08.010

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  16 in total

Review 1.  Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?

Authors:  Zhi-Fa Lv; Fu-Cai Wang; Hui-Lie Zheng; Ben Wang; Yong Xie; Xiao-Jiang Zhou; Nong-Hua Lv
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 2.  Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.

Authors:  Sinéad M Smith; Colm O'Morain; Deirdre McNamara
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype.

Authors:  Li-Juan Zhao; Yan-Qiang Huang; Bing-Pu Chen; Xiao-Qiang Mo; Zan-Song Huang; Xiao-Feng Huang; Lian-Deng Wei; Hong-Yu Wei; Yuan-Hong Chen; Hua-Ying Tang; Gan-Rong Huang; Yan-Chun Qin; Xiao-Hua Li; Lu-Yao Wang
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

4.  Extremely High Prevalence of Metronidazole-Resistant Helicobacter pylori Strains in Mountain People (Karen and Hmong) in Thailand.

Authors:  Ratha-korn Vilaichone; Thawee Ratanachu-Ek; Pornpen Gamnarai; Supakarn Chaithongrat; Tomahisa Uchida; Yoshio Yamaoka; Varocha Mahachai
Journal:  Am J Trop Med Hyg       Date:  2016-02-15       Impact factor: 2.345

5.  The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study.

Authors:  Jyh-Ming Liou; Chi-Yang Chang; Mei-Jyh Chen; Chieh-Chang Chen; Yu-Jen Fang; Ji-Yuh Lee; Jeng-Yih Wu; Jiing-Chyuan Luo; Tai-Cherng Liou; Wen-Hsiung Chang; Cheng-Hao Tseng; Chun-Ying Wu; Tsung-Hua Yang; Chun-Chao Chang; Hsiu-Po Wang; Bor-Shyang Sheu; Jaw-Town Lin; Ming-Jong Bair; Ming-Shiang Wu
Journal:  PLoS One       Date:  2015-05-05       Impact factor: 3.240

6.  Improved Helicobacter pylori Eradication Rate of Tailored Triple Therapy by Adding Lactobacillus delbrueckii and Streptococcus thermophilus in Northeast Region of Thailand: A Prospective Randomized Controlled Clinical Trial.

Authors:  Taweesak Tongtawee; Chavaboon Dechsukhum; Wilairat Leeanansaksiri; Soraya Kaewpitoon; Natthawut Kaewpitoon; Ryan A Loyd; Likit Matrakool; Sukij Panpimanmas
Journal:  Gastroenterol Res Pract       Date:  2015-06-08       Impact factor: 2.260

7.  Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations.

Authors:  Muhammad Miftahussurur; Ari Fahrial Syam; Iswan Abbas Nusi; Dadang Makmun; Langgeng Agung Waskito; Lukman Hakim Zein; Fardah Akil; Willy Brodus Uwan; David Simanjuntak; I Dewa Nyoman Wibawa; Jimmy Bradley Waleleng; Alexander Michael Joseph Saudale; Fauzi Yusuf; Syifa Mustika; Pangestu Adi; Ummi Maimunah; Hasan Maulahela; Yudith Annisa Ayu Rezkitha; Phawinee Subsomwong; Dadik Rahardjo; Rumiko Suzuki; Junko Akada; Yoshio Yamaoka
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

8.  Gastric Cancer and Gastrointestinal Stromal Tumors Could be Causes of non-Helicobacter Pylori non-NSAIDs Peptic Ulcers in Thailand

Authors:  Pattama Kiatpapan; Ratha korn Vilaichone; Peranart Chotivitayatarakorn; Varocha Mahachai
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01

9.  High Fluoroquinolone Resistant Strains of Helicobacter pylori in the Golden triangle

Authors:  Ratha Korn Vilaichone; Thawee Ratanachu ek; Pornpen Gamnarai; Phawinee Subsomwong; Tomahisa Uchida; Yoshio Yamaoka; Varocha Mahachai
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

10.  Characteristics and Risk Factors of Helicobacter pylori Associated Gastritis: A Prospective Cross-Sectional Study in Northeast Thailand.

Authors:  Taweesak Tongtawee; Soraya Kaewpitoon; Natthawut Kaewpitoon; Chavaboon Dechsukhum; Wilairat Leeanansaksiri; Ryan A Loyd; Likit Matrakool; Sukij Panpimanmas
Journal:  Gastroenterol Res Pract       Date:  2016-03-02       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.